Jie Lu1, Blake K Montgomery2, Grégoire P Chatain1, Alejandro Bugarini3, Qi Zhang3, Xiang Wang3, Nancy A Edwards3, Abhik Ray-Chaudhury3, Marsha J Merrill3, Russell R Lonser4, Prashant Chittiboina5. 1. Neurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, MD, United States. 2. Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, MD, United States; Department of Orthopedic Surgery, Stanford Medicine, Stanford, CA, United States. 3. Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, MD, United States. 4. Department of Neurological Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH, United States. 5. Neurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, MD, United States; Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, MD, United States. Electronic address: prashant.chittiboina@nih.gov.
Abstract
BACKGROUND: Pre-operative detection of corticotropin (ACTH) secreting microadenomas causing Cushing's disease (CD) improves surgical outcomes. Current best magnetic resonance imaging fails to detect up to 40% of these microadenomas. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is specific, but not sensitive in detecting corticotropinomas. Theoretically, secretagogue stimulation with corticotropin releasing hormone (CRH) could improve detection of adenomas with 18F-FDG PET. Previous attempts with simultaneous CRH stimulation have failed to demonstrate increased 18F-FDG uptake in corticotropinomas. We hypothesized that CRH stimulation leads to a delayed elevation in glucose uptake in corticotropinomas. METHODS: Clinical data was analyzed for efficacy of CRH in improving 18FDG-PET detection of corticotropinomas in CD. Glucose transporter 1 (GLUT1) immunoreactivity was performed on surgical specimens. Ex-vivo, viable cells from these tumors were tested for secretagogue effects (colorimetric glucose uptake), and for fate of intracellular glucose (glycolysis stress analysis). Validation of ex-vivo findings was performed with AtT-20 cells. RESULTS: CRH increased glucose uptake in human-derived corticotroph tumor cells and AtT-20, but not in normal murine or human corticotrophs (p < 0.0001). Continuous and intermittent (1 h) CRH exposure increased glucose uptake in AtT-20 with maximal effect at 4 h (p = 0.001). Similarly, CRH and 8-Br-cAMP led to robust GLUT1 upregulation and increased membrane translocation at 2 h, while fasentin suppressed baseline (p < 0.0001) and CRH-mediated glucose uptake. Expectedly, intra-operatively collected corticotropinomas demonstrated GLUT1 overexpression. Lastly, human derived corticotroph tumor cells demonstrated increased glycolysis and low glucose oxidation. CONCLUSION: Increased and delayed CRH-mediated glucose uptake differentially occurs in adenomatous corticotrophs. Delayed secretagogue-stimulated 18F-FDG PET could improve microadenoma detection. Published by Elsevier B.V.
BACKGROUND: Pre-operative detection of corticotropin (ACTH) secreting microadenomas causing Cushing's disease (CD) improves surgical outcomes. Current best magnetic resonance imaging fails to detect up to 40% of these microadenomas. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is specific, but not sensitive in detecting corticotropinomas. Theoretically, secretagogue stimulation with corticotropin releasing hormone (CRH) could improve detection of adenomas with 18F-FDG PET. Previous attempts with simultaneous CRH stimulation have failed to demonstrate increased 18F-FDG uptake in corticotropinomas. We hypothesized that CRH stimulation leads to a delayed elevation in glucose uptake in corticotropinomas. METHODS: Clinical data was analyzed for efficacy of CRH in improving 18FDG-PET detection of corticotropinomas in CD. Glucose transporter 1 (GLUT1) immunoreactivity was performed on surgical specimens. Ex-vivo, viable cells from these tumors were tested for secretagogue effects (colorimetric glucose uptake), and for fate of intracellular glucose (glycolysis stress analysis). Validation of ex-vivo findings was performed with AtT-20 cells. RESULTS:CRH increased glucose uptake in human-derived corticotroph tumor cells and AtT-20, but not in normal murine or human corticotrophs (p < 0.0001). Continuous and intermittent (1 h) CRH exposure increased glucose uptake in AtT-20 with maximal effect at 4 h (p = 0.001). Similarly, CRH and 8-Br-cAMP led to robust GLUT1 upregulation and increased membrane translocation at 2 h, while fasentin suppressed baseline (p < 0.0001) and CRH-mediated glucose uptake. Expectedly, intra-operatively collected corticotropinomas demonstrated GLUT1 overexpression. Lastly, human derived corticotroph tumor cells demonstrated increased glycolysis and low glucose oxidation. CONCLUSION: Increased and delayed CRH-mediated glucose uptake differentially occurs in adenomatous corticotrophs. Delayed secretagogue-stimulated 18F-FDG PET could improve microadenoma detection. Published by Elsevier B.V.
Authors: Aaron L Miller; M Scott Webb; Alicja J Copik; Yongxin Wang; Betty H Johnson; Raj Kumar; E Brad Thompson Journal: Mol Endocrinol Date: 2005-04-07
Authors: M Bergström; C Muhr; K Ericson; H Lundqvist; A Lilja; L Eriksson; G Blomquist; B Långström; P Johnström Journal: Neuroradiology Date: 1987 Impact factor: 2.804
Authors: P W Saphier; M Faria; A Grossman; D H Coy; G M Besser; B Hodson; M Parkes; E A Linton; P J Lowry Journal: J Endocrinol Date: 1992-06 Impact factor: 4.286
Authors: Jacqueline Boyle; Nicholas J Patronas; James Smirniotopoulos; Peter Herscovitch; William Dieckman; Corina Millo; Dragan Maric; Grégoire P Chatain; Christina Piper Hayes; Sarah Benzo; Gretchen Scott; Nancy Edwards; Abhik Ray Chaudhury; Maya B Lodish; Susmeeta Sharma; Lynnette K Nieman; Constantine A Stratakis; Russell R Lonser; Prashant Chittiboina Journal: Endocrine Date: 2019-05-06 Impact factor: 3.633
Authors: Mª Carmen Ocaña; Beatriz Martínez-Poveda; Manuel Marí-Beffa; Ana R Quesada; Miguel Ángel Medina Journal: Sci Rep Date: 2020-04-09 Impact factor: 4.379
Authors: Akm Khyrul Wara; Shijia Wang; Chun Wu; Fang Fang; Stefan Haemmig; Brittany N Weber; Ceren O Aydogan; Yevgenia Tesmenitsky; Hassan Aliakbarian; John R Hawse; Malayannan Subramaniam; Lei Zhao; Peter T Sage; Ali Tavakkoli; Amanda Garza; Lydia Lynch; Alexander S Banks; Mark W Feinberg Journal: Cell Rep Date: 2020-12-29 Impact factor: 9.423
Authors: Joseph Longo; Aleksandra A Pandyra; Paweł Stachura; Mark D Minden; Aaron D Schimmer; Linda Z Penn Journal: Mol Oncol Date: 2020-08-25 Impact factor: 6.603